ActHIB vaccine recalled in Japan

March 11, 2011

Sanofi Pasteur and Daiichi Sankyo on Friday announced a recall of the ActHIB vaccine in Japan after an "unidentified substance" was found in two syringes.

Daiichi is the Japan marketer of the vaccine manufactured by Sanofi Pasteur, a wing of Paris-headquartered Sanofi-Aventis. The drug is used to prevent bacterial infections causing pneumonia and meningitis.

However, Daiichi told AFP most of the 1.3 million dose shipment had already been used and only a small percentage remained.

A Sanofi Pasteur official told AFP the company was checking how many vaccines had been used.

The official in Tokyo said that the doses "were manufactured on a production line dedicated to the Japanese market".

"They were delivered between September 2010 and late January 2011 but were produced about six months earlier," he added.

Japan's health ministry last week suspended the vaccine along with Pfizer's Prevenar, also used against that can cause and .

The ministry is investigating the recent deaths of six infants who were administered either one or both of the treatments, or in combination with other drugs.

Both Pfizer and Sanofi-Aventis have vouched for the safety of their vaccines and said they are cooperating with the investigation in .

Related Stories

Recommended for you

Researchers identify drug that alleviates opioid withdrawal

January 30, 2017

Opioid use and abuse is a significant social, health and economic issue in Canada. Researchers at the University of Calgary's Faculty of Veterinary Medicine (UCVM) and Hotchkiss Brain Institute (HBI) have discovered that ...

Detecting counterfeit medicines

January 27, 2017

Bernard Naughton and Dr David Brindley from Oxford University's Saïd Business School and Medical Sciences Division discuss the problems of identifying fake, substandard and expired medicines.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.